Aprinoia
Taiwan · $51.1M raised
- Business Model
- B2B
- Website
- aprinoia.com
- Total Funding
- $51.1M
- Last Round
- $40.0M Series CJan 2021
- Rounds
- 2
About
Biotechnology company developing precision medicines for neurodegenerative diseases including tauopathies and alpha-synucleinopathies.
Summary
Aprinoia is a Biotech company based in Taiwan. It has raised $51.1M in total across 2 rounds, most recently a $40.0M Series C round in Jan 2021. Investors include Daiwa Corporate Investment, KTB Network and DCI Partners.
Sign up to view the funding chart
Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.
Funding History
Jan 2021
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company